Use of immune checkpoint inhibitors (ICIs), including antibodies against programmed cell death protein 1 (PD-1) or its ligand PD-L1, has significantly improved overall survival (OS) in NSCLC (8). Here, PDCD1 is linked to non-small cell lung carcinoma.